Patient pathway
I have a mutation result
A pathway for turning a genomic report into better questions.
What this situation means
- Mutation results can change treatment and trial conversations, but the exact variant and cancer subtype matter.
What not to assume
- Do not assume every mutation has an approved targeted therapy.
Information to gather
- Full genomic report
- exact gene and variant
- BRAF/NRAS/KIT/NTRK status
- prior therapies
Bring to the surgeon
- Would new tissue help clarify subtype or mutation status?
Bring to the oncologist
- Which findings are actionable?
- Which findings are trial-search terms?
- Should a specialty center review the report?
Bring to the trial team
- Which mutation terms should be searched in trial listings?
Related database records
source-backed record
NRAS-mutant melanoma
source-backed record
BRAF V600-mutant melanoma
source-backed record
KIT-altered melanoma
source-backed record
NTRK fusion-positive melanoma
Related cohort threads
lived experience only
Trial search terms that helped you find better conversations
Share search phrases, registry links, and questions that made trial conversations clearer.
Sources with the medical details
- Melanoma Treatment (PDQ) - Health Professional Version. Accessed 2026-05-20.
- First-in-human phase I dose-escalation and dose-expansion trial of HL-085 in advanced melanoma harboring NRAS mutations. Accessed 2026-05-20.
- Tunlametinib Capsules approved with conditions for marketing by China NMPA. Accessed 2026-05-20.
- NCT06008106: Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma. Accessed 2026-05-20.
- NCI: Drugs Approved for Melanoma, including encorafenib and binimetinib. Accessed 2026-05-20.
- NCI: Dabrafenib-Trametinib Combination Approved for Melanoma and Thyroid Cancer. Accessed 2026-05-20.
- Drugs Approved for Melanoma. Accessed 2026-05-20.